hidden
hidden

Updated NCCN Guidelines for Treatment of Acute Myeloid Leukemia Include Cord Blood Stem Cells

The National Comprehensive Cancer Network (NCCN) announced updates to the Clinical Practice Guidelines in Oncology(TM) for Acute Myeloid Leukemia (AML) to include cord blood as an official stem cell treatment option.

October 19, 2009 - The National Comprehensive Cancer Network (NCCN) announced updates to the NCCN Clinical Practice Guidelines in Oncology(TM) for Acute Myeloid Leukemia (AML), the most common acute leukemia affecting adults. One update of note is the inclusion of cord blood as an official stem cell treatment option.

Although AML is a relatively rare disease, an estimated 12,810 new cases will be diagnosed in the United States in 2009, its incidence appears to be increasing as the population ages. The NCCN Clinical Practice Guidelines in Oncology are developed and updated through an evidence-based process with explicit review of the scientific evidence integrated with expert judgment by multidisciplinary panels of physicians from NCCN Member Institutions. The most recent version of this and all the NCCN Guidelines are available free of charge at NCCN.org.

View Full Story